Avalo Therapeutics(AVTX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates WAYNE, PA, August 7, 2025 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2025. "The team has made tremendous progress on the execution of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS). We have enr ...